Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Blog Article

Abstract Background In patients with hepatitis C virus (HCV) and SELENIUM 50 MCG malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment.However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies.Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare Polocrosse during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL).

The patient completed five additional courses of R-CHOP without hepatic toxicity.A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion.Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.